The round included investments by Softbank Vision, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments and Irving Investors and was backed by existing investor Gilde Healthcare and select members of LUMICKS' management team.
LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. These instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells.
For press release and media attention, please see:
LUMICKS Technologies - https://lumicks.com/lumicks-raises-93-million-in-series-d-financing/
NautaDutilh's team consisted of Paul van der Bijl, Ruud Smits, Sanne Meester, Leanne Meurs, Joppe Schoute and Daan Hagelstein.